Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. [Radium isotopes]
Hydroxyurea was evaluated as a possible radiation sensitizer in 130 evaluable women with Stages IIB and IIIB (International Federation of Gynecology and Obstetrics) carcinoma of the uterine cervix. This was a prospective double-blind randomized study in which hydroxyurea or placebo was compared in conjunction with continuous or split-course radiation therapy. Of all patients with Stage IIB cancer without biopsy proof of aortic node metastasis, a significant improvement in survival (P < 0.01) was achieved in the hydroxyurea group (74.0 per cent) as compared to the patients receiving placebo (43.5 per cent). In women with Stage IIIB cervical cancer there was a trend toward longer survival in those receiving hydroxyurea (52.1 per cent) as compared to those receiving placebo (33.3 per cent). However, there was a statistically significant improvement in survival in those women with Stage IIIB cervical cancer who had staging done at operation, were found to have negative para-aortic nodes, and subsequently received continuous radiation therapy (90.9 per cent) as compared to those receiving split-course therapy (29.4 per cent) (P = 0.005).
- Research Organization:
- Roswell Park Memorial Inst., Buffalo
- OSTI ID:
- 5333410
- Journal Information:
- Am. J. Obstet. Gynecol.; (United States), Vol. 129:4; Conference: 59. annual meeting of the American Radium Society, Las Vegas, NV, USA, 26 Apr 1977
- Country of Publication:
- United States
- Language:
- English
Similar Records
Survival of nonsurgically staged patients with negative lymphangiograms who had Stage IIB carcinoma of the cervix treated by pelvic radiation plus hydroxyurea
Early Clinical Outcomes and Toxicity of Intensity Modulated Versus Conventional Pelvic Radiation Therapy for Locally Advanced Cervix Carcinoma: A Prospective Randomized Study
Related Subjects
CARCINOMAS
RADIOTHERAPY
HYDROXYUREA
RADIOSENSITIVITY EFFECTS
RADIUM ISOTOPES
BIOLOGICAL RADIATION EFFECTS
UROGENITAL SYSTEM DISEASES
RADIATION SOURCE IMPLANTS
RADIOSENSITIZERS
SURVIVAL TIME
WOMEN
ALKALINE EARTH ISOTOPES
AMIDES
ANIMALS
BIOLOGICAL EFFECTS
DISEASES
DRUGS
FEMALES
HYDROXY COMPOUNDS
ISOTOPES
MAMMALS
MAN
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
PRIMATES
RADIATION EFFECTS
RADIATION SOURCES
RADIOLOGY
RESPONSE MODIFYING FACTORS
THERAPY
VERTEBRATES
560161* - Radionuclide Effects
Kinetics
& Toxicology- Man